Vital Therapies Added to NASDAQ Biotechnology Index
December 11 2017 - 8:00AM
Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company
developing ELAD®, a cell-based therapy targeting the treatment of
acute forms of liver failure, today announced that it has been
selected for addition to the NASDAQ Biotechnology Index®, which
will become effective prior to the open of U.S. markets Monday,
December 18, 2017.
The NASDAQ Biotechnology Index (NBI) contains
securities of NASDAQ-listed companies classified according to the
Industry Classification Benchmark as either Biotechnology or
Pharmaceuticals which also meet other eligibility criteria.
Companies in the NBI must meet eligibility requirements, including
minimum market capitalization, and average daily trading volume,
among other criteria. The NASDAQ Biotechnology Index is
re-ranked annually and forms the basis for a number of Exchange
Traded Funds (ETFs) including the iShares NASDAQ Biotechnology ETF.
For more information about the NASDAQ Biotechnology Index visit
https://indexes.nasdaqomx.com.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic
company developing a cell-based therapy targeting the treatment of
acute forms of liver failure. The Company’s ELAD System is an
extracorporeal human allogeneic cellular liver therapy currently in
phase 3 clinical trials. Vital Therapies, Inc. is based in San
Diego, California. Vital Therapies® and ELAD® are trademarks
of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al KildaniVice President,
Investor Relations and Business Development
858-673-6840akildani@vitaltherapies.com
VITAL THERAPIES INC (NASDAQ:VTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
VITAL THERAPIES INC (NASDAQ:VTL)
Historical Stock Chart
From Sep 2023 to Sep 2024